Hypometabolism in the medial temporal and frontal regions is significantly associated with TAR DNA binding protein of 43 kDa (TDP-43) proteinopathy. Combining fluorodeoxyglucose (FDG)-PET readings from these regions may be a potential tool for predicting Alzheimer-related TDP-43 proteinopathy in patients with Alzheimer's disease (AD) spectrum pathology.
Why this matters
There is strong clinical and neuropathologic evidence linking TDP-43 deposition with the neurodegeneration attributed to AD and dementia. Currently, the only way to detect TDP-43 deposition is at autopsy, so there is an unmet need to predict TDP-43 status antemortem so that potential candidates for TDP-43 targeted treatment in clinical trials can be identified. These results show that predicting TDP-43 levels in living patients is feasible, which may therefore aid future research on therapies targeting TDP-43 deposition and also assist prognosis in clinical settings.